摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(4-acetylpiperazin-1-yl)-2-fluorobenzaldehyde | 1445902-92-0

中文名称
——
中文别名
——
英文名称
4-(4-acetylpiperazin-1-yl)-2-fluorobenzaldehyde
英文别名
4-(4-Acetylpiperazin-1-yl)-2-fluorobenzaldehyde
4-(4-acetylpiperazin-1-yl)-2-fluorobenzaldehyde化学式
CAS
1445902-92-0
化学式
C13H15FN2O2
mdl
——
分子量
250.273
InChiKey
SLSVORZSODGVGT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    466.6±45.0 °C(Predicted)
  • 密度:
    1.252±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    18
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    40.6
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Minor Structural Change to Tertiary Sulfonamide RORc Ligands Led to Opposite Mechanisms of Action
    摘要:
    A minor structural change to tertiary sulfonamide RORc ligands led to distinct mechanisms of action. Co-crystal structures of two compounds revealed mechanistically consistent protein conformational changes. Optimized phenyl-sulfonamides were identified as RORc agonists while benzylsulfonamides exhibited potent inverse agonist activity. Compounds behaving as agonists in our biochemical assay also gave rise to an increased production of IL-17 in human PBMCs whereas inverse agonists led to significant suppression of IL-17 under the same assay conditions. The most potent inverse agonist compound showed >180-fold selectivity over the ROR isoforms as well as all other nuclear receptors that were profiled.
    DOI:
    10.1021/ml500420y
  • 作为产物:
    描述:
    1-乙酰哌嗪4-溴-1-(二甲氧基甲基)-2-氟苯 在 palladium diacetate 、 sodium t-butanolate2-二环己基磷-2',6'-二异丙氧基-1,1'-联苯盐酸 作用下, 以 1,4-二氧六环四氢呋喃 为溶剂, 反应 32.0h, 以60%的产率得到4-(4-acetylpiperazin-1-yl)-2-fluorobenzaldehyde
    参考文献:
    名称:
    [EN] BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS
    [FR] DÉRIVÉS DE BENZYLSULFONAMIDE UTILISÉS EN TANT QUE MODULATEUR DE RORC
    摘要:
    式(I)的化合物或其药用可接受的盐,其中m、n、A、X1、X2、X3、X4、R1、R2、R3a、R3b、R4a和R4b的定义如本文所述。还公开了制备这些化合物的方法,并将这些化合物用于治疗炎症性疾病,如关节炎。
    公开号:
    WO2013092941A1
点击查看最新优质反应信息

文献信息

  • BENZYL SULFONAMIDE DERIVATIVES AS RORC MODULATORS
    申请人:Genentech, Inc.
    公开号:US20130190288A1
    公开(公告)日:2013-07-25
    Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, A, X 1 , X 2 , X 3 , X 4 , R 1 , R 2 , R 3a , R 3b , R 4a and R 4b are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    化合物I的公式或其药学上可接受的盐,其中m、n、A、X1、X2、X3、X4、R1、R2、R3a、R3b、R4a和R4b的定义如本文所述。还公开了制备该化合物的方法,并将该化合物用于治疗炎症性疾病,如关节炎。
  • Aryl sulfamide and sulfamate derivatives as RORc modulators
    申请人:Genentech, Inc.
    公开号:US08912219B2
    公开(公告)日:2014-12-16
    Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, A, X1, X2, X3, X4, X5, X6, Y, Z, G, R1a, R2a, R1b, R2b, R3, R4, R5 and R6 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    公式I的化合物或其药学上可接受的盐,其中m,n,p,q,r,A,X1,X2,X3,X4,X5,X6,Y,Z,G,R1a,R2a,R1b,R2b,R3,R4,R5和R6的定义如本文所述。还揭示了制备该化合物的方法,并将该化合物用于治疗炎症性疾病,如关节炎。
  • Benzyl sulfonamide derivatives as RORc modulators
    申请人:Genentech, Inc.
    公开号:US09216988B2
    公开(公告)日:2015-12-22
    Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, A, X1, X2, X3, X4, R1, R2, R3a, R3b, R4a and R4b are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    化合物I的公式或其药学上可接受的盐,其中m、n、A、X1、X2、X3、X4、R1、R2、R3a、R3b、R4a和R4b的定义如本文所述。还公开了制备该化合物的方法,并使用该化合物治疗炎症性疾病,如关节炎。
  • US20140275032A1
    申请人:——
    公开号:——
    公开(公告)日:——
  • BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS
    申请人:F.Hoffmann-La Roche AG
    公开号:EP2794584A1
    公开(公告)日:2014-10-29
查看更多